早期乳腺癌辅助化疗的优化选择应当平衡其疗效和毒副反应。美国临床肿瘤协会进行了一项研究,旨在探讨同样进行4或6个周期辅助化疗时,紫杉醇单药(single-agent Paclitaxel,T)的疗效是否优于多柔比星联合环磷酰胺(Doxorubicin and C...早期乳腺癌辅助化疗的优化选择应当平衡其疗效和毒副反应。美国临床肿瘤协会进行了一项研究,旨在探讨同样进行4或6个周期辅助化疗时,紫杉醇单药(single-agent Paclitaxel,T)的疗效是否优于多柔比星联合环磷酰胺(Doxorubicin and Cyclophosphamide,AC),单药T方案的毒副反应是否小于AC方案。展开更多
1文献来源
Veronesi U, Orecchia R, Luini A, et al. European Institute of Oncology. Intraoperative radiotherapy during breast conserving surgery: A study on 1,822 cases treated with electrons [J].Breast Cancer Res Tr...1文献来源
Veronesi U, Orecchia R, Luini A, et al. European Institute of Oncology. Intraoperative radiotherapy during breast conserving surgery: A study on 1,822 cases treated with electrons [J].Breast Cancer Res Treat, 2010, 124(1) : 141-151.展开更多
文摘早期乳腺癌辅助化疗的优化选择应当平衡其疗效和毒副反应。美国临床肿瘤协会进行了一项研究,旨在探讨同样进行4或6个周期辅助化疗时,紫杉醇单药(single-agent Paclitaxel,T)的疗效是否优于多柔比星联合环磷酰胺(Doxorubicin and Cyclophosphamide,AC),单药T方案的毒副反应是否小于AC方案。
文摘1文献来源
Veronesi U, Orecchia R, Luini A, et al. European Institute of Oncology. Intraoperative radiotherapy during breast conserving surgery: A study on 1,822 cases treated with electrons [J].Breast Cancer Res Treat, 2010, 124(1) : 141-151.